Developmental toxicity assessment of tanezumab, an anti-nerve growth factor monoclonal antibody, in cynomolgus monkeys (Macaca fascicularis)

Reproductive Toxicology

Volumn 53, Issue , 2015, Pages 105-118

  Bowman, Christopher J ^a   Evans, Mark ^a   Cummings, Thomas ^a   Oneda, Satoru ^b   Butt, Mark ^c   Hurst, Susan ^a   Gremminger, Jessica lyn ^a   Shelton, David ^a   Kamperschroer, Cris ^a   Zorbas, Mark ^a  

^a PFIZER INC   (United States)

^b Formerly of SNBL USA Ltd   (United States)

^c Tox Path Specialists LLC   (United States)

Author keywords

Developmental toxicity; Monoclonal antibody; Nerve growth factor; Non human primate; Pregnancy; Tanezumab

Indexed keywords

TANEZUMAB; MONOCLONAL ANTIBODY; NERVE GROWTH FACTOR RECEPTOR;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CHILD GROWTH; CONTROLLED STUDY; DEVELOPMENTAL TOXICITY; FEMALE; GROWTH RETARDATION; INFANT; INFANT MORTALITY; MACACA FASCICULARIS; MALE; MORBIDITY; NONHUMAN; PRENATAL DRUG EXPOSURE; RISK ASSESSMENT; SENSORY NERVE; STILLBIRTH; ANIMAL; ANTAGONISTS AND INHIBITORS; BIRTH WEIGHT; DRUG EFFECTS; EMBRYO DEVELOPMENT; FETOMATERNAL TRANSFUSION; FETUS DEVELOPMENT; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PATHOLOGY; PREGNANCY; PRENATAL EXPOSURE; SKIN;

MACACA FASCICULARIS; PRIMATES;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIRTH WEIGHT; EMBRYONIC DEVELOPMENT; FEMALE; FETAL DEVELOPMENT; MACACA FASCICULARIS; MALE; MATERNAL-FETAL EXCHANGE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RECEPTOR, NERVE GROWTH FACTOR; SKIN; STILLBIRTH;

EID: 84930179824     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2014.10.004     Document Type: Article

References (42)

1. Mantyh P.W., Koltzenburg M., Mendell L.M., Tive L., Shelton D.L. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology 2011, 115:189-204.
2. Svensson P., Cairns B.E., Wang K., Arendt-Nielsen L. Injection of nerve growth factor into human masseter muscle evokes long-lasting mechanical allodynia and hyperalgesia. Pain 2003, 104:241-247.
3. Shelton D.L., Zeller J., Ho W.H., Pons J., Rosenthal A. Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis. Pain 2005, 116:8-16.
4. Brown M., Murphy F., Radin D., Davignon I., Smith M., West C. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. J Pain 2012, 13:790-798.
5. Evans R.J., Moldwin R.M., Cossons N., Darekar A., Mills I.W., Scholfield D. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol 2011, 185:1716-1721.
6. Katz N., Borenstein D.G., Birbara C., Bramson C., Nemeth M.A., Smith M.D., et al. Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain 2011, 152:2248-2258.
7. Lane N.E., Schnitzer T.J., Birbara C.A., Mokhtarani M., Shelton D.L., Smith M.D., et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010, 363:1521-1531.
8. Rich K.M., Yip H.K., Osborne P.A., Schmidt R.E., Johnson E.M. Role of nerve growth factor in the adult dorsal root ganglia neuron and its response to injury. J Comp Neurol 1984, 230:110-118.
9. Bjorling D.E., Beckman M., Clayton M.K., Wang Z.Y. Modulation of nerve growth factor in peripheral organs by estrogen and progesterone. Neuroscience 2002, 110:155-167.
10. Dhobale M., Mehendale S., Pisal H., Nimbargi V., Joshi S. Reduced maternal and cord nerve growth factor levels in preterm deliveries. Int J Dev Neurosci 2012, 30:99-103.
11. Tometten M., Blois S., Arck P.C. Nerve growth factor in reproductive biology: link between the immune, endocrine and nervous system?. Chem Immunol Allergy 2005, 89:135-148.
12. Tometten M., Blois S., Kuhlmei A., Stretz A., Klapp B.F., Arck P.C. Nerve growth factor translates stress response and subsequent murine abortion via adhesion molecule-dependent pathways. Biol Reprod 2006, 74:674-683.
13. Aloe L., Simone M.D., Properzi F. Nerve growth factor: a neurotrophin with activity on cells of the immune system. Microsc Res Tech 1999, 45:285-291.
14. Bonini S., Rasi G., Bracci-Laudiero M.L., Procoli A., Aloe L. Nerve growth factor: neurotrophin or cytokine?. Int Arch Allergy Immunol 2003, 131:80-84.
15. Fiore M., Chaldakov G.N., Aloe L. Nerve growth factor as a signaling molecule for nerve cells and also for the neuroendocrine-immune systems. Rev Neurosci 2009, 20:133-145.
16. Aloe L., Rocco M.L., Bianchi P., Manni L. Nerve growth factor: from the early discoveries to the potential clinical use. J Transl Med 2012, 10:239.
17. Noga O., Peiser M., Altenähr M., Schmeck B., Wanner R., Dinh Q.T., et al. Selective induction of nerve growth factor and brain-derived neurotrophic factor by LPS and allergen in dendritic cells. Clin Exp Allergy 2008, 38:473-479.
18. Torcia M., Bracci-Laudiero L., Lucibello M., Nencioni L., Labardi D., Rubartelli A., et al. Nerve growth factor is an autocrine survival factor for memory B lymphocytes. Cell 1996, 85:345-356.
19. Kronfeld I., Kazimirsky G., Gelfand E.W., Brodie C. NGF rescues human B lymphocytes from anti-IgM induced apoptosis by activation of PKCzeta. Eur J Immunol 2002, 32:136-143.
20. Torcia M., De Chiara G., Nencioni L., Ammendola S., Labardi D., Lucibello M., et al. Nerve growth factor inhibits apoptosis in memory B lymphocytes via inactivation of p38 MAPK, prevention of Bcl-2 phosphorylation, and cytochrome c release. J Biol Chem 2001, 276:39027-39036.
21. Linker R., Gold R., Luhder F. Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination. Crit Rev Immunol 2009, 29:43-68.
22. Scuri M., Samsell L., Piedimonte G. The role of neurotrophins in inflammation and allergy. Inflamm Allergy Drug Targets 2010, 9:173-180.
23. Seidel M.F., Herguijuela M., Forkert R., Otten U. Nerve growth factor in rheumatic diseases. Semin Arthr Rheum 2010, 40:109-126.
24. Zorbas M., Hurst S., Shelton D., Evans M., Finco D., Butt M. A multiple-dose toxicity study of tanezumab in cynomolgus monkeys. Regul Toxicol Pharmacol 2011, 59:334-342.
25. Armour K.L., Atherton A., Williamson L.M., Clark M.R. The contrasting IgG-binding interactions of human and herpes simplex virus Fc receptors. Biochem Soc Trans 2002, 30:495-500.
26. National Research Council The guide for the care and use of laboratory animals 1996, National Academy Press, Washington, DC.
27. Makori N., Watson R.E., Hogrefe C.E., Lalayeva N., Oneda S. Object discrimination and reversal learning in infant and juvenile non-human primates in a non-clinical laboratory. J Med Primatol 2013, 42:147-157.
28. Neubert H., Clark T.H., Deng S., Hurst S.I. Serum beta-nerve growth factor concentrations in pregnant female, nonpregnant female, and male cynomolgus monkeys. Neuroreport 2014, 25:829-832.
29. Butt M., Evans M., Bowman C.J., Cummings T., Oneda S., Shelton D., et al. Morphologic, stereologic, and morphometric evaluation of the nervous system in young cynomolgus monkeys (Macaca fascicularis) following maternal administration of tanezumab, a monoclonal antibody to nerve growth factor. Toxicol Sci 2014, 10.1093/toxsci/kfu192.
30. Hurst S.I., Arends R., Hughey D.B., Vergara G., Shelton D., Liras J. Interspecies scaling of tanezumab, an anti-NGF antibody, and comparison of the projected human pharmacokinetic parameters to single-dose clinical data 2009, Annual Scientific Meeting of the American Association of Pharmaceutical Scientists (AAPS), Los Angeles, CA.
31. Martin P.L., Weinbauer G.F. Developmental toxicity testing of biopharmaceuticals in nonhuman primates: previous experience and future directions. Int J Toxicol 2010, 29:552-568.
32. Moffat G.J., Retter M.W., Kwon G., Loomis M., Hock M.B., Hall C., et al. Placental transfer of a fully human IgG2 monoclonal antibody in the cynomolgus monkey, rat, and rabbit: a comparative assessment from during organogenesis to late gestation. Birth Defects Res B: Dev Reprod Toxicol 2014, 101:178-188.
33. Kanai-Azuma M., Kanai Y., Matsuda H., Kurohmaru M., Tachi C., Yazaki K., et al. Nerve growth factor promotes giant-cell transformation of mouse trophoblast cells in vitro. Biochem Biophys Res Commun 1997, 231:309-315.
34. Jarvis P., Srivastav S., Vogelwedde E., Stewart J., Mitchard T., Weinbauer G.F. The cynomolgus monkey as a model for developmental toxicity studies: variability of pregnancy losses, statistical power estimates, and group size considerations. Birth Defects Res B: Dev Reprod Toxicol 2010, 89:175-187.
35. Sesbuppha W., Chantip S., Dick E.J., Schlabritz-Loutsevitch N.E., Guardado-Mendoza R., Butler S.D., et al. Stillbirths in Macaca fascicularis. J Med Primatol 2008, 37:169-172.
36. Luppi P., Levi-Montalcini R., Bracci-Laudiero L., Bertolini A., Arletti R., Tavernari D., et al. NGF is released into plasma during human pregnancy: an oxytocin-mediated response?. Neuroreport 1993, 4:1063-1065.
37. Kidron D., Bernheim J., Aviram R. Placental findings contributing to fetal death, a study of 120 stillbirths between 23 and 40 weeks gestation. Placenta 2009, 30:700-704.
38. Plunkett B.A., Fitchev P., Doll J.A., Gerber S.E., Cornwell M., Greenstein E.P., et al. Decreased expression of pigment epithelium derived factor (PEDF), an inhibitor of angiogenesis, in placentas of unexplained stillbirths. Reprod Biol 2008, 8:107-120.
39. Emanueli C., Salis M.B., Pinna A., Graiani G., Manni L., Madeddu P. Nerve growth factor promotes angiogenesis and arteriogenesis in ischemic hindlimbs. Circulation 2002, 106:2257-2262.
40. Aloe L., Cozzari C., Calissano P., Levi-Montalcini R. Somatic and behavioral postnatal effects of fetal injections of nerve growth factor antibodies in the rat. Nature 1981, 291:413-415.
41. Crowley C., Spencer S.D., Nishimura M.C., Chen K.S., Pitts-Meek S., Armanini M.P., et al. Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons. Cell 1994, 76:1001-1011.
42. Stockham S.L., Scott M.A. Leukocytes. The fundamentals of veterinary clinical pathology 2002, 49-83. Iowa State Press, Ames, IA.